Newsroom |  Contact Us

Effective Treatment for Fluid Overload

Aquadex SmartFlow™ System

Aquapheresis therapy, delivered by the Aquadex SmartFlow System, uses a simplified approach to ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. Compared to renal replacement devices used for ultrafiltration, the Aquadex SmartFlow System is smaller and more portable.

Physicians can specify and adjust the exact amount and rate of fluid to be removed from each patient, resulting in a gradual reduction that has been shown to have no significant clinical impact on blood pressure, heart rate, or the balance of electrolytes (e.g. sodium, potassium, etc.) in the body.1

Up to 500 mL per hour of excess fluid can be removed with no clinically significant impact on electrolyte balance.1,2

Aquadex SmartFlow: New features

Simple

  • Easy set-up and monitoring allows for up to 4:1 patient to nurse ratio
  • Highly automated with only one setting required to begin
  • Smart alarms/alerts prompt action when necessary

Flexible

  • Perform therapy through peripheral or central venous access
  • Portable system with small 35 ml extracorporeal volume meets patient needs in a multitude of clinical settings
  • Customizable HCT monitor can be tailored to individual patient needs

Smart

  • HCT sensor provides real time measurement of % blood volume change
  • SvO2 monitoring provides insights into tissue oxygen delivery
  • Filter Alert prompts action to extend filter life and reduce therapy time

 

Aquadex SmartFlow System Coiled Dual Lumen Extended Length Catheter (dELC)

 


Aquadex SmartFlow System Technology

Aquadex SmartFlow System Console The Aquadex SmartFlow System is an FDA cleared system designed to simply, safely, and precisely remove excess fluid (primarily excess salt and water) from patients suffering from fluid overload who have not responded to medical management, including diuretics. With the Aquadex SmartFlow, medical practitioners can specify and control the amount of fluid to be extracted in a safe, predictable, and effective manner with the option of utilizing hematocrit monitoring to help inform therapy decisions.2

Rx Only
Indication:
 Continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

References
¹RAPID Trial: Bart BA, et al. J Am Coll  Cardiol. 2005 Dec 6; 46(11): 2043-2046.
2SAFE Trial: Jaski BE, et al. J Card Fail. 2003 Jun; 9(3): 227-231.

CHF Solutions